Please assess the completion status of the following clinical trial:

Trial Title: The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or nonpregnant female patients \>18 years of age.~2. Has a clinical diagnosis of Retinal Vein Occlusion (RVO) in the study eye.~3. Best-Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score ≥ 20 (20/400 Snellen equivalent), and ≤75 in the study eye (20/32 Snellen equivalent).~4. Central Subfield Thickness (CST) ≥310 microns measured by Spectral Domain Optical Coherence Tomography (SD-OCT) in the study eye.~Exclusion Criteria:~1. Intravitreal (IVT) injection of anti-VEGF: Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA/Roche, Basel, Switzerland) or ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA) within 1 month and aflibercept (Eylea®; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA, and Bayer HealthCare Pharmaceuticals, Berlin, Germany) within 2 months in the study eye.~2. Intraocular or periocular corticosteroid injection within 3 months, dexamethasone implant (Ozurdex, Allergan, Dublin, Ireland) within 6 months, Retisert (Bausch and Lomb, Bridge water, NJ) within 1 year, or fluocinolone acetonide implant (Iluvien, Alimera Sciences, Alpharetta, GA) within 3 years in the study eye.~3. Macular laser photocoagulation treatment in the study eye.~4. Topical ophthalmic nonsteroidal anti-inflammatory drugs in the study eye within a month.~5. Any significant media opacity that could hinder the evaluation of the retina or ocular condition causing decreased vision other than RVO.~6. IOP \>22 mm Hg, or history of steroid-induced ocular hypertension; uncontrolled glaucoma.~7. Past vitreoretinal or glaucoma surgery in the study eye.~8. Uncontrolled systemic disease that could hinder follow-up, immunodeficiency, or any other systemic contraindication for steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg Triamcinolone Acetonide (TA)/ Suprachoriodal Injection (Type: EXPERIMENTAL): Suprachoroidal injection of 4 mg in 100 μL of TA was administered as a single injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).